Dishman Carbogen Amcis subsidiary forms strategic ADC alliance with Celonic Group

On October 7, 2025, Dishman Carbogen Amcis Limited announced a strategic alliance between its wholly-owned subsidiary, CARBOGEN AMCIS AG, and Celonic Group. This partnership aims to deliver a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing platform. The collaboration combines Celonic's biologics capabilities with CARBOGEN AMCIS's expertise in payload synthesis, conjugation, and sterile fill-finish, creating an end-to-end solution for ADC innovators.

The integrated offering includes cell line development and antibody production from Celonic, alongside payload and linker synthesis, at-scale manufacturing, ADC conjugation, and sterile fill-finish from CARBOGEN AMCIS. The alliance also provides regulatory support and CMC documentation for IND, IMPD, and BLA filings, streamlining the supply chain and accelerating timelines from early-stage development to commercial launch.

This partnership addresses the biopharmaceutical sector's need for simplified ADC development by offering a single accountable partner. CARBOGEN AMCIS, which delivered its first ADC project in 2005, has dedicated conjugation suites in Switzerland and manufacturing capabilities in France, while Celonic operates a Development and Innovation Center in Basel, Switzerland, and GMP manufacturing facilities in Heidelberg, Germany.